EXOSC4 and prostate adenocarcinoma: TCGA PanCancer analysis revealed that EXOSC4 showed high-level amplification above 5% in nine different cancer types, including Breast invasive carcinoma (BRCA), Esophageal carcinoma (ESCA), Head and Neck squamous cell carcinoma (HNSC), Liver hepatocellular carcinoma (LIHC), Ovarian serous cystadenocarcinoma (OV), Pancreatic adenocarcinoma (PAAD), Prostate adenocarcinoma (PRAD), Stomach adenocarcinoma (STAD), and Uterine Carcinosarcoma (UCS) (Figure 1B and Figure S1A, and Tables S2 and S3).